These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 11460031)

  • 1. [Immunotherapy for melanoma: how can tolerance be overcome?].
    Robert C
    Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
    [No Abstract]   [Full Text] [Related]  

  • 2. Self-recognition and tumor response to immunotherapy.
    Ernstoff MS
    J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in cellular immunotherapy for malignant melanoma].
    López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F
    Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The unfulfilled promise of melanoma vaccines.
    Livingston P
    Clin Cancer Res; 2001 Jul; 7(7):1837-8. PubMed ID: 11448892
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytotoxic T-cell immune response against melanoma antigens].
    Ayyoub M
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
    [No Abstract]   [Full Text] [Related]  

  • 8. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma antigens and targets for vaccination.
    Kang N; Truman H; Sanders R; Kupsch J
    Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunology and immunotherapy of human malignant melanoma.
    Bystryn JC
    Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer. Cancer immunotherapy is more than a numbers game.
    Offringa R
    Science; 2006 Oct; 314(5796):68-9. PubMed ID: 17023641
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma: the good news, the bad ones and what to do next.
    Marincola FM; Ferrone S
    Semin Cancer Biol; 2003 Dec; 13(6):387-9. PubMed ID: 15001156
    [No Abstract]   [Full Text] [Related]  

  • 16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Active specific immunotherapy of malignant melanoma].
    Lotem M; Shiloni E; Ingber A; Peretz T
    Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [General principles and first clinical trials of therapeutic vaccines against cancer].
    Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
    Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Special report: vaccines for the treatment of malignant melanoma.
    Tecnologica MAP Suppl; 2001 Apr; ():19-20. PubMed ID: 11718143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.